Catatonia

Catatonia is a complex neuropsychiatric syndrome characterized by a marked disturbance in motor, behavioral, and emotional functioning, manifesting as a spectrum of symptoms ranging from stupor and mutism to agitation, echolalia, and stereotypies.

Definition and Overview

Catatonia is not a standalone diagnosis but a syndrome that can occur in the context of various psychiatric, medical, and neurological disorders. It is defined by a cluster of signs and symptoms that involve abnormal movement, speech, and behavior. Historically, catatonia was strongly associated with schizophrenia, but contemporary research recognizes it as a nonspecific syndrome that can accompany mood disorders (especially bipolar disorder and major depressive disorder), general medical conditions, substance-induced states, and neurodevelopmental disorders. The syndrome is often underdiagnosed, yet it is highly treatable once identified.

Historical Background

The term "catatonia" was first introduced by German psychiatrist Karl Ludwig Kahlbaum in 1874 in his monograph Die Katatonie oder das Spannungsirresein (Catatonia or Tension Insanity). Kahlbaum described it as a distinct motor syndrome that could occur in various mental illnesses, with core features of motor tension, stupor, and alternating excitement. Later, Emil Kraepelin incorporated catatonia as a subtype of dementia praecox, and Eugen Bleuler included it in his conceptualization of schizophrenia. For much of the 20th century, catatonia was viewed primarily as a subtype of schizophrenia in diagnostic systems such as the DSM and ICD. However, accumulating evidence showed that catatonia is more frequently associated with mood disorders and medical conditions, leading to its reclassification in modern diagnostic criteria (DSM-5) as a specifier that can apply to several disorders.

Clinical Features

Catatonia presents with a wide variety of signs and symptoms, which are often grouped into two main forms: retarded (hypokinetic) and excited (hyperkinetic), though mixed presentations are common.

Hypokinetic Catatonia

• Stupor: Profoundly reduced or absent spontaneous movement and speech, with the patient appearing immobile and unresponsive.
• Mutism: Absence of verbal output, though the person may be able to speak if prompted intensely.
• Negativism: Resistance to instructions or to attempts to move the patient, often with automatic opposition.
• Posturing: Maintaining a fixed, often bizarre posture for extended periods.
• Catalepsy (waxy flexibility): The patient allows limbs to be moved into positions and then holds them there for an unusually long time.
• Rigidity: Increased muscle tone, often persistent.
• Staring: Fixed gaze with reduced blinking.
• Grimacing: Sustained facial contortions.
• Echophenomena (echolalia, echopraxia): Automatic repetition of another person's words or movements.

Hyperkinetic Catatonia

• Excitement: Purposeless, excessive motor activity, often repetitive and agitated.
• Stereotypies: Repetitive, non-goal-directed movements (e.g., rocking or pacing).
• Agitation: Psychomotor agitation without clear environmental triggers.
• Impulsivity: Sudden, unpredictable behaviors, sometimes including aggression.
• Mannerisms: Caricatures of normal movements or gestures.
• Verbigeration: Meaningless repetition of words or phrases.

Malignant Catatonia

A severe, life-threatening form characterized by hyperthermia, autonomic instability (tachycardia, hypertension, diaphoresis), and altered consciousness. It resembles neuroleptic malignant syndrome (NMS) and can progress to death without prompt treatment.

Causes and Associated Conditions

Catatonia can arise from diverse etiologies:

• Psychiatric disorders: Most commonly associated with mood disorders (bipolar mania and major depression), schizophrenia (especially the catatonic subtype), and other psychotic disorders. Less frequently seen in post-traumatic stress disorder, obsessive-compulsive disorder, and autistic spectrum disorders.
• Medical and neurological conditions: Infections (encephalitis, meningitis), autoimmune encephalitis (e.g., anti-NMDA receptor encephalitis), metabolic disturbances (uremia, hepatic encephalopathy), thyroid dysfunction, stroke, traumatic brain injury, brain tumors, and Parkinson's disease.
• Substance-related: Intoxication or withdrawal from psychoactive substances (e.g., alcohol, benzodiazepines, stimulants, cannabis, or antipsychotics).
• Medication-induced: Certain drugs, especially antipsychotics, can precipitate catatonia, though the syndrome itself is not identical to NMS.
• Neurodevelopmental disorders: Catatonia can occur in autism spectrum disorder, often presenting as regression or worsening of baseline behaviors.

Diagnosis

Diagnosis is based on clinical observation and the presence of a core set of features. Standardized rating scales, such as the Bush-Francis Catatonia Rating Scale (BFCRS), aid in identification and severity assessment. The DSM-5 requires the presence of three or more of the following 12 features: stupor, catalepsy, waxy flexibility, mutism, negativism, posturing, mannerisms, stereotypy, agitation, grimacing, echolalia, and echopraxia. A thorough medical workup—including blood tests, neuroimaging, EEG, and lumbar puncture—is essential to rule out underlying organic causes.

Treatment

Effective treatment often leads to rapid resolution of symptoms.

Benzodiazepines

The first-line pharmacological treatment for catatonia is lorazepam, a benzodiazepine. A typical approach involves a challenge test with intravenous or intramuscular lorazepam (often 1–2 mg), which can produce a dramatic improvement within minutes. Oral benzodiazepines are then used for maintenance.

Electroconvulsive Therapy (ECT)

ECT is highly effective, especially for patients who do not respond to benzodiazepines or who have malignant catatonia. It is considered the gold standard for severe or refractory cases.

Other Medications

• Barbiturates (e.g., amobarbital) have historical use but are now rarely employed.
• NMDA receptor antagonists (e.g., memantine, amantadine) and GABA-ergic drugs (e.g., valproate) may be used off-label in refractory cases.
• Antipsychotics are generally avoided because they can exacerbate catatonia or precipitate NMS, though they may be cautiously reintroduced after resolution if needed for an underlying psychotic disorder.

Supportive Care

Patients with catatonia require monitoring for dehydration, malnutrition, deep vein thrombosis, and complications of immobility. Malignant catatonia demands intensive care management with hydration, cooling, and ECT.

Prognosis

The prognosis of catatonia depends on the underlying cause and promptness of treatment. With appropriate intervention, most patients recover fully or experience significant improvement. Delayed treatment or unrecognized catatonia can lead to prolonged morbidity, and malignant catatonia has a mortality rate of 3–10% even with treatment. Recurrence is possible, particularly in the context of mood disorders. Long-term management focuses on treating the primary condition and preventing relapses.